SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is seeing a significant surge in trading volume and price following the FDA approval of Yartemlea, its first-in-class therapy for a severe transplant-associated complication. The community is actively debating the stock's substantial undervaluation, fueled by its pipeline validation, a major licensing deal with Novo Nordisk, and potential for a short squeeze. Many foresee considerable upside, with discussions circling around valuations far exceeding current levels, while some also acknowledge concerns about possible dilution.

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

Cosmos (ATOM) is trending as its community actively works on a significant tokenomics redesign to shift from inflationary rewards to a revenue-based model, aiming to enhance value accrual and mitigate sell pressure. This move is a major talking point, with some users hopeful for long-term growth given ATOM's foundational role in interoperability and ecosystem expansion. However, others remain critical of its recent price action despite attractive staking yields, leading to an active debate about ATOM's future utility within the evolving blockchain landscape.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax is trending significantly following the announcement that Sanofi is acquiring the company for $15.50 per share, a move set to enhance Sanofi's adult immunization portfolio with Dynavax's key vaccine assets. The community is buzzing with discussions about the offer's fairness, with many long-term shareholders expressing frustration over the valuation compared to the stock's historical performance, while others celebrate the substantial immediate gains. This development underscores the continued strategic consolidations within the biotech vaccine sector.

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.

Mimedx Group Inc

MiMedx Group is trending as recent CMS policy changes are poised to dramatically reshape the advanced wound care market by curbing fraud and prioritizing products with strong clinical evidence. The community is actively debating how these regulations will eliminate many higher-priced competitors, creating a significant market share opportunity for MDXG's proven offerings. Investors are keenly focused on how this shift towards evidence-based reimbursement could drive the company's long-term growth despite initial pricing adjustments.

RAWW MILK COIN

RAWW MILK COIN is buzzing as its community highlights a year of sustained development and continuous content drops, from new webtoons and "Truth Series" videos to an album and game updates. The sentiment centers on RAWW building a unique "anti-degen" lifestyle and expanding into a full cultural universe, rather than just being a typical meme coin. This consistent delivery, even through market volatility, underscores its distinct philosophy and community-driven longevity.

Inflection Point Acquisition Corp. IV is a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Andrew Stephen Gundlach and Michel Combes on June 24, 2024 and is headquartered in New York, NY.

Inflection Point Acquisition Corp. IV - Ordinary Shares - Class A

Bleichroeder Acquisition Corp I

Bleichroeder Acquisition Corp I ($BACQ) is generating significant buzz following multiple bullish reports from Citron Research, highlighting its compelling risk/reward ahead of a merger with Merlin Labs. The community is actively discussing Merlin's advanced AI-enabled autonomous flight technology, substantial defense contracts, and partnerships with major aerospace primes, all seen as strong growth catalysts for the defense tech SPAC. Many view the current valuation favorably due to its perceived limited downside and significant upside potential post-merger.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is trending higher following significant regulatory relief, including the OCC removing a consent order and the Fed closing a supervisory notice, alongside strong earnings that underscore its ongoing transformation. The community is actively discussing its impressive multi-year rally, driven by broader financial sector optimism and ongoing corporate buybacks, though some express caution regarding its overbought technical conditions.

snowball is the first token in the world that uses the pumpfun creator fees to automatically marketmake itself aggressively.

snowball

SNOWBALL CRYPTO is trending as a new Solana-based project, with the community actively discussing its potential as a "scam dev detector" aimed at preventing "rug pulls." Many believe this innovative utility could be a "game changer" for new crypto launches, driving significant interest despite some caution among users regarding its rapid ascent.

Ethereum Classic

Ethereum Classic is trending prominently, fueling a polarized discussion within the crypto community. While many investors voice frustration over its prolonged underperformance relative to major cryptocurrencies, a strong cohort sees current valuations as a significant buying opportunity. This dedicated group anticipates ETC is poised for a substantial catch-up surge as the broader altcoin market evolves.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is trending amid intense focus on its pivotal role in silicon photonics and co-packaged optics, critical for next-generation AI data centers via collaborations like TSMC's COUPE platform. The community is keenly discussing the potential for substantial revenue growth from these innovations, balancing high anticipation with historical skepticism about stock performance and market maker influence. As a key enabler for surging AI infrastructure demand, investors are watching for a significant revaluation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Innoviva (NASDAQ:INVA) Share Price Crosses Above Two Hundred Day Moving Average - Here's Why

Innoviva (NASDAQ:INVA) Stock Crosses Above Two Hundred Day Moving Average - Here's Why...

Innoviva, Inc. (NASDAQ:INVA) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Innoviva, Inc. (NASDAQ:INVA - Get Free Report) have been given an average rating of "Moderate Buy" by the seven research firms that are presently covering the company, Marketbeat Ratings...

FDA Approves Innoviva's NUZOLVENCE, First-in-Class Oral Treatment For Gonorrhea

(RTTNews) - Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (INVA), announced that the U.S. Food and Drug Administration approved NUZOLVENCE (zoliflodacin) for oral suspension, a...

U.S. FDA Approves NUZOLVENCE (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced that the U.S. Food and Drug Administration (FDA) has approved NUZOLVENCE (zoliflodacin) for oral...

Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea

Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced the publication of positive results from a pivotal Phase 3 trial evaluating its investigational...

State Board of Administration of Florida Retirement System Cuts Stake in Innoviva, Inc. $INVA

State Board of Administration of Florida Retirement System decreased its holdings in Innoviva, Inc. (NASDAQ:INVA - Free Report) by 80.4% in the second quarter, according to its most recent 13F filing...

Innoviva, Inc. $INVA Shares Purchased by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership raised its stake in Innoviva, Inc. (NASDAQ:INVA - Free Report) by 85.3% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The...

Boston Partners Boosts Holdings in Innoviva, Inc. $INVA

Boston Partners lifted its position in shares of Innoviva, Inc. (NASDAQ:INVA - Free Report) by 40.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 875,084...

Innoviva, Inc. $INVA Shares Purchased by American Century Companies Inc.

American Century Companies Inc. raised its position in Innoviva, Inc. (NASDAQ:INVA - Free Report) by 23.3% in the 2nd quarter, according to the company in its most recent 13F filing with the...

Jefferies Financial Group Inc. Increases Stake in Innoviva, Inc. $INVA

Jefferies Financial Group Inc. raised its holdings in shares of Innoviva, Inc. (NASDAQ:INVA - Free Report) by 421.0% during the 2nd quarter, according to the company in its most recent Form 13F...

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

INVA
Innoviva Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest INVA News

INVAInnoviva Inc